Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice

Ohya, K. Imamura, M. Teraoka, Y. Uchida, T. Fujino, H. Nakahara, T. Ono, A. Murakami, E. Yamauchi, M. Kawaoka, T. Miki, D. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Aikata, H. Ishida, Y. Tateno, C. Song, H. Miyayama, Y. Hijikata, M. Chayama, K.

Biochem Biophys Res Commun. 2021 Jun 25;559:78-83. doi: 10.1016/j.bbrc.2021.04.062. Epub 2021 Apr 29.

Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model

Dent, M. Hamorsky, K. Vausselin, T. Dubuisson, J. Miyata, Y. Morikawa, Y. Matoba, N.
Cell Mol Gastroenterol Hepatol. 2021;11(1):185-198. doi: 10.1016/j.jcmgh.2020.08.009. Epub 2020 Aug 27.

Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion

Ma, C. D. Imamura, M. Talley, D. C. Rolt, A. Xu, X. Wang, A. Q. Le, D. Uchida, T. Osawa, M. Teraoka, Y. Li, K. Hu, X. Park, S. B. Chalasani, N. Irvin, P. H. Dulcey, A. E. Southall, N. Marugan, J. J. Hu, Z. Chayama, K. Frankowski, K. J. Liang, T. J.

Nat Microbiol. 2020 Aug 31. doi: 10.1038/s41564-020-0781-2.

Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir

Wang, T. Babusis, D. Park, Y. Niu, C. Kim, C. Zhao, X. Lu, B. Ma, B. Muench, R. C. Sperger, D. Ray, A. S. Murakami, E.

Drug Metab Pharmacokinet. 2020 Jun;35(3):334-340. doi: 10.1016/j.dmpk.2020.04.333. Epub 2020 Apr 16.

Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection

Cheng, X. Uchida, T. Xia, Y. Umarova, R. Liu, C. J. Chen, P. J. Gaggar, A. Suri, V. Mucke, M. M. Vermehren, J. Zeuzem, S. Teraoka, Y. Osawa, M. Aikata, H. Tsuji, K. Mori, N. Hige, S. Karino, Y. Imamura, M. Chayama, K. Liang, T. J.

J Clin Invest. 2020 Mar 12. pii: 135616. doi: 10.1172/JCI135616.

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice

Osawa, M. Uchida, T. Imamura, M. Teraoka, Y. Fujino, H. Nakahara, T. Ono, A. Murakami, E. Kawaoka, T. Miki, D. Tsuge, M. Hiramatsu, A. Abe-Chayama, H. Hayes, C. N.

J Gen Virol. 2019 Jul;100(7):1123-1131.

Humanized Mouse Models for the Study of Hepatitis C and Host Interactions

Yong, K. S. M. Her, Z. Chen, Q.

Cells. 2019 Jun 17;8(6). pii: cells8060604.

Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development

Lupberger, J. Croonenborghs, T. Roca Suarez, A. A. Van Renne, N. Juhling, F. Oudot, M. A. Virzi, A. Bandiera, S. Jamey, C. Meszaros, G. Brumaru, D. Mukherji, A. Durand, S. C. Heydmann, L. Verrier, E. R. El Saghire, H. Hamdane, N. Bartenschlager, R. Fereshetian, S. Ramberger, E. Sinha, R. Nabian, M. Everaert, C. Jovanovic, M. Mertins, P. Carr, S. A. Chayama, K. Dali-Youcef, N. Ricci, R. Bardeesy, N. M. Fujiwara, N. Gevaert, O. Zeisel, M. B. Hoshida, Y. Pochet, N. Baumert, T. F.

Gastroenterology. 2019 Apr 9. pii: S0016-5085(19)35670-7. doi: 10.1053/j.gastro.2019.04.003.

HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response

Hamdane, N. Juhling, F. Crouchet, E. El Saghire, H. Thumann, C. Oudot, M. A. Bandiera, S. Saviano, A. Ponsolles, C. Roca Suarez, A. A. Li, S. Fujiwara, N. Ono, A. Davidson, I. Bardeesy, N. Schmidl, C. Bock, C. Schuster, C. Lupberger, J. Habersetzer, F. Doffoel, M. Piardi, T. Sommacale, D. mamura, M. Uchida, T. Ohdan, H. Aikata, H. Chayama, K. Boldanova, T. Pessaux, P. Fuchs, B. C. Hoshida, Y. Zeisel, M. B. Duong, F. H. T. Baumert, T. F.

Gastroenterology. 2019 Mar 2. pii: S0016-5085(19)32506-5. doi: 10.1053/j.gastro.2019.02.038.

Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection

Ishida, Y. Kakuni, M. Bang, B. R. Sugahara, G. Lau, D. T. Tateno-Mukaidani, C. Li, M. Gale, M., Jr. Saito, T.

J Interferon Cytokine Res. 2019 Mar;39(3):133-146. doi: 10.1089/jir.2018.0103.

Ribonucleotide reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-dependent proteasomal degradation

Kitab, B. Satoh, M. Ohmori, Y. Munakata, T. Sudoh, M. Kohara, M. Tsukiyama-Kohara, K.

J Biol Chem. 2019 Feb 12. pii: RA118.004397. doi: 10.1074/jbc.RA118.004397.

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure

Teraoka, Y. Uchida, T. Imamura, M. Hiraga, N. Osawa, M. Kan, H. Saito, Y. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

J Gen Virol. 2018 Jun 19. doi: 10.1099/jgv.0.001091.

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

Teraoka, Y. Uchida, T. Imamura, M. Osawa, M. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157.

Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

Rolt, A. Le, D. Hu, Z. Wang, A. Q. Shah, P. Singleton, M. Hughes, E. Dulcey, A. E.He, S. Imamura, M. Uchida, T. Chayama, K. Xu, X. Marugan, J. J. Liang, T. J.

J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093/infdis/jiy039.

A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage

Reddy, B. U. Mullick, R. Kumar, A. Sharma, G. Bag, P. Roy, C. L. Sudha, G. Tandon, H. Dave, P. Shukla, A. Srinivasan, P. Nandhitha, M.Srinivasan, N. Das, S.

Antiviral Res. 2017 Dec 7;150:47-59.

Hepatitis C replication inhibitors that target the viral NS4B protein

Miller, J. F. Chong, P. Y. Shotwell, J. B. Catalano, J. G. Tai, V. W. Fang, J. Banka, A. L. Roberts, C. D. Youngman, M. Zhang, H. Xiong, Z. Mathis, A. Pouliot, J. J. Hamatake, R. K. Price, D. J. Seal, J. W., 3rd Stroup, L. L. Creech, K. L. Carballo, L. H. Todd, D. Spaltenstein, A. Furst, S. Hong, Z. Peat, A. J.

J Med Chem. 2014 Mar 13;57(5):2107-20

Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus

Hamana, A. Takahashi, Y. Uchida, T. Nishikawa, M. Imamura, M. Chayama, K. Takakura, Y.

Antiviral Res. 2017 Aug 31;146:130-138.

Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells

Chida, T. Ito, M. Nakashima, K. Kanegae, Y. Aoshima, T. Takabayashi, S. Kawata, K. Nakagawa, Y. Yamamoto, M. Shimano, H. Matsuura, T. Kobayashi, Y. Suda, T. Suzuki, T.

Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.

Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus

Miyaki, E. Hiraga, N. Imamura, M. Uchida, T.  Kan, H.  Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Serikawa, M. Aikata, H. Ochi, H. Ishida, Y. Tateno, C. Ohdan, H. Chayama, K.

PLoS One. 2017 Mar 2;12(3):e0172412.

Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology

Uchida, T. Imamura, M. Kan, H. Hiraga, N. Hayes, C. N. Tsuge, M. Abe-Chayama, H. Aikata, H. Makokha, G. N. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

J Gen Virol. 2017 Jan 28. doi: 10.1099/jgv.0.000726.